TENAX THERAPEUTICS FACES NASDAQ DELISTING THREAT

TL;DR

**TENX got a delisting notice from Nasdaq, stock likely to tank.**

AI Summary

Tenax Therapeutics, Inc. announced on January 9, 2024, that it received a notice from the Nasdaq Stock Market indicating its failure to meet continued listing standards. This means the company's stock, currently trading under the ticker TENX, is at risk of being delisted from Nasdaq. This matters to investors because delisting often leads to decreased liquidity and investor confidence, potentially causing the stock price to fall significantly.

Why It Matters

Delisting from Nasdaq can severely impact a company's stock by reducing its visibility and making it harder for investors to trade shares, often leading to a significant drop in stock value.

Risk Assessment

Risk Level: high — The risk of delisting is a severe event for a public company, often leading to a substantial loss in shareholder value and liquidity.

Analyst Insight

A smart investor would consider selling shares of Tenax Therapeutics, Inc. (TENX) to avoid potential further losses due to the delisting risk and reduced liquidity, or at least closely monitor the company's plan to regain Nasdaq compliance.

Key Players & Entities

• Tenax Therapeutics, Inc. (company) — the registrant facing delisting
• Nasdaq Stock Market (company) — the exchange from which Tenax Therapeutics may be delisted
• January 9, 2024 (date) — date of the earliest event reported regarding the delisting notice

Forward-Looking Statements

• Tenax Therapeutics, Inc. stock (TENX) will experience significant downward pressure. (TENX) — high confidence, target: Q1 2024
• The company will attempt to regain compliance with Nasdaq listing standards. (Tenax Therapeutics, Inc.) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share TENX The Nasdaq
• $416 — receive cash compensation at a rate of $416 per hour for Mr. Hoffman's services, wh

Filing Documents

• tenx_8k.htm (8-K) — 29KB
• 0001654954-24-000523.txt ( ) — 151KB
• tenx-20240109.xsd (EX-101.SCH) — 6KB
• tenx-20240109_lab.xml (EX-101.LAB) — 14KB
• tenx-20240109_cal.xml (EX-101.CAL) — 1KB
• tenx-20240109_pre.xml (EX-101.PRE) — 9KB
• tenx-20240109_def.xml (EX-101.DEF) — 2KB
• tenx_8k_htm.xml (XML) — 4KB

01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 11, 2024, Tenax Therapeutics, Inc. (the "Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") regarding compliance with Nasdaq Listing Rule 5550(a)(4) (the "Rule") which requires the Company to have a minimum of 500,000 publicly held shares. The letter from Nasdaq indicated that according to its calculations, as of January 3, 2024, the day after the Company effected a 1-for-80 reverse split of its common stock, the Company no longer meets the requirements of the Rule. This notice of noncompliance has no immediate impact on the continued listing or trading of the Company's securities on the Nasdaq Capital Market, which will continue to be listed and traded on Nasdaq, subject to the Company's compliance with the other Nasdaq continued listing requirements. In accordance with Nasdaq rules, we have until February 26, 2024 to provide the Staff with a specific plan to achieve and sustain compliance with all listing requirements of The Nasdaq Capital Market, including the time frame for completion of this plan. After reviewing our plan, Nasdaq will provide written notice of their decision. If Nasdaq does not accept our plan, we will have the opportunity to appeal their decision to a hearings panel. We intend to consider options available to us to achieve compliance with the Nasdaq listing rules and provide our plan to Nasdaq by February 26, 2024. There can be no assurance that we will be able to achieve and sustain compliance with the publicly held shares requirement or will otherwise be in compliance with the other listing standards for The Nasdaq Capital Market. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c), (e) On January 9, 2024, the Company's Board of Directors (the "Board

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 10.1 Consulting Agreement dated October 14, 2021, by and between Tenax Therapeutics, Inc. and Danforth Advisors, LLC (certain confidential portions (as indicated therein) of this exhibit have been omitted) (incorporated by reference to Exhibit 10.20 to the Company's Form 10-K for the period ended December 31, 2021, filed with the SEC on March 29, 2022). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 12, 2024 Tenax Therapeutics, Inc. By: /s/ Christopher T. Giordano Christopher T. Giordano President and Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR